Tag: BACLIB-News

SEATTLE, WA – 30 March, 2026 – Microbiology diagnostics company Pataigin today appointed Michael Chen as Medical Director to facilitate implementation of BACLIB in the clinical diagnostic lab.

SEATTLE, WA – 30 March, 2022 – Microbiology diagnostics company Pataigin today appointed Deborah A. Elvins as an advisor to the company on business strategy and other business matters.

LISBON, Portugal: Results will be presented from a study of Pataigin’s rapid bacterial ID assay, direct from clinical specimens.

VIENNA, Austria, BALTIMORE Maryland, and SEATTLE, Washington – 13 July 2021: At the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID, www.eccmid.org), Pataigin introduced the BACLIB Rapid Lipid Extraction Kit for microbial identification and colistin resistance detection.

Today, the US NIH awarded Pataigin a research grant to further development of Pataigin’s Rigel antimicrobial susceptibility test.

Today, Pataigin founder Prof. Robert Ernst presented results of a new assay that determines microbial ID and colistin resistance in one hour, direct from clinical specimens. The assay uses lipid microbiology with the FLAT extraction technique to allow colistin resistance to be rapidly determined without culture.

Scientific Reports today published a paper describing the FLAT rapid extraction method that allows identification of bacteria and fungi in one hour. Determination of colistin resistance in Gram-negative bacteria is also demonstrated. The paper was authored by Pataigin personnel in collaboration with the labs of BACLIB inventors Prof. Robert Ernst and Prof. David Goodlett.

In a paper published in Scientific Reports, Pataigin collaborators demonstrated identification of the ESKAPE pathogens using the BACLIB method licenses by Pataigin.

Today, at a joint meeting of the University of Maryland, Baltimore (UMB) and Johns Hopkins University, Pataigin was awarded a $25,000 Maryland Department of Commerce Life award for Pataigin’s application of lipid fingerprint technology licensed from UMB. Pataigin has developed a test, called BACLIB, that inexpensively identifies bacteria and fungi causing infections in less than an hour. Pataigin plans on using its award funding to validate tests for high-priority antibiotic-resistant microbes such as ESKAPE pathogens, which include Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter, Pseudomonas aeruginosa and Enterobacter.

BALTIMORE, Dec. 08, 2015 (GLOBE NEWSWIRE) — University of Maryland (UM) Ventures and Pataigin announced today that the University of Maryland, Baltimore (UMB) has granted Pataigin worldwide, exclusive licensing rights to UMB patents and technology for a method to quickly and accurately identify dangerous pathogens. Robert Ernst, Ph.D., associate professor of microbial pathogenesis at UMB School of Dentistry, and David Goodlett, Ph.D., professor of pharmaceutical sciences at UMB School of Pharmacy, are patent inventors. The University of Washington is also a co-owner on one of the patents. Erik Nilsson, who has headed software and mass spectrometry companies for nearly 20 years, will serve as Pataigin’s CEO.